Replies to post #72088 on Biotech Values

[DewDiligence]

Re: Efficacy of MS drugs

Do you (or anyone else) have a good link or data on the various efficacy rate of the Interferon's in MS (and Tysabri). Or is it better to not be lazy and just read the labels? :-)

Here you go:

http://www.fda.gov/cder/foi/label/2007/103628s5115lbl.pdf (Avonex)
http://www.fda.gov/cder/foi/label/2003/103471s5032lbl.pdf (Betaseron)
http://www.fda.gov/cder/foi/label/2005/103780s5062lbl.pdf (Rebif)
http://www.fda.gov/cder/foi/label/2001/20622s15lbl.pdf (Copaxone)
http://www.fda.gov/cder/foi/label/2008/125104s106lbl.pdf (Tysabri)

Don’t forget to post your summary :- )

[genisi]

UTHR FREEDOM-M study:

As I have posted (on the PLX board), having 21 extra patients seemed too little to me. Adding 100 more, so the majority (~150) of patients will have access to the 0.25mg pill, makes a p-value of 0.01 in this trial achievable, imo.

On MS, this one has a summery:

http://emedicine.medscape.com/article/1146199-treatment